How Much Does NGS Lab Software Cost in 2026?

What an NGS laboratory build actually costs

Across the clinical laboratory work Digital Heroes has delivered, this build separates into a system that runs the laboratory and a platform that owns the interpretation. The laboratory system, covering accessioning with requisition capture, batch, plate and library preparation tracking, assay versioning, pipeline orchestration with quality gates and turnaround time monitoring, runs $110,000 to $220,000 and ships in 16 to 22 weeks. The interpretation platform adding a laboratory owned variant knowledge base, reclassification surveillance, templated sign out, amended report handling and payer aware billing handoff runs $300,000 to $700,000 phased over 9 to 15 months.

Most laboratories scope this as a laboratory information management project and are surprised by where the money goes. The wet laboratory tracking is the smaller half. The expensive half is everything that has to remain true after the report is signed: which pipeline version produced this call, which classification applied on the date of sign out, and what happens when that classification changes two years later while the patient is still alive and being treated.

Scope band one: accessioning through pipeline

Line items from recent molecular diagnostics projects:

• Discovery and specimen and assay data model: $16,000. How a specimen relates to an aliquot, a library, a run and a report. Every downstream feature either fits this model or fights it.
• Accessioning: $28,000. Requisition capture, ordering physician details, clinical indication and specimen adequacy, entered once and reused everywhere rather than retyped at each stage.
• Batch, plate and library preparation tracking: $34,000. Positional tracking through extraction and library preparation, because a plate map error is invisible until two patients receive each other's results.
• Assay versioning and panel definitions: $30,000. Which genes, which regions, which reporting thresholds, versioned so that a report from eighteen months ago is still explainable today.
• Pipeline orchestration with quality gates: $46,000. Running the bioinformatics with coverage, contamination and call rate gates that stop a poor run before it reaches a reviewer rather than after.
• Turnaround time monitoring: $18,000. Where cases sit and why, which is the number your ordering physicians actually judge you on.

That set totals $172,000, which is a typical first release for a laboratory running a handful of assays at moderate volume.

Scope band two: the knowledge base and sign out

The second band is what makes the laboratory's interpretation an asset rather than a service it rents. A laboratory owned variant knowledge base with classification evidence runs about $95,000, holding not just the call but the evidence and the reasoning behind it, versioned by date. Reclassification surveillance is roughly $70,000: when a variant classification changes, the system identifies every previously reported patient affected and produces the list, which is the single highest value feature in the category and the one packaged products handle least well.

Templated sign out with report variants by ordering physician and payer requirement is about $80,000. Amended report handling with prior version reproducibility is roughly $55,000. Payer aware billing handoff, carrying the prior authorisation and coding data the claim needs, is about $60,000, and integrating a second sequencer or instrument is around $45,000.

What pushes the cost up

• Assay launch frequency. Each new assay brings a pipeline version, a report template, reporting thresholds and a validation package. A laboratory launching four assays a year carries that cost four times a year, permanently.
• Somatic and germline together. Different classification frameworks, different reporting conventions and different reflex logic. One model bent to cover both produces reports that satisfy neither audience.
• Instrument variety. Each sequencer platform and each liquid handler is its own integration with its own run metadata format.
• Multiple report audiences. Oncologists, geneticists and referring generalists want different levels of detail, and each variant of the report template is real work to build and maintain.
• Reference and annotation source changes. Every annotation source you depend on has its own release cadence, and pinning versions so old reports stay explainable is engineering rather than configuration.

What brings the cost down

• One assay family first. Build for your highest volume panel and extend afterwards. Building for every assay you might ever launch delays the one you actually run today.
• Deferring reclassification surveillance. It is the highest value feature and it can wait until the base pipeline is trusted, provided you capture classification with a date from day one so the history exists when you build it.
• Report templates as configuration. Let a laboratory director change wording without a release. This pays back on every assay launch afterwards.
• Keeping billing handoff simple initially. A structured export to your billing team is far cheaper than a full payer aware integration and adequate at moderate volume.

A worked example that adds up

A laboratory running three panels, reporting roughly 400 cases a month, currently paying per case to an interpretation vendor while the wet laboratory runs on spreadsheets and a shared drive, with two new assays planned for next year. First release, line by line: discovery and specimen and assay data model $16,000, accessioning $28,000, batch, plate and library preparation tracking $34,000, assay versioning and panel definitions $30,000, pipeline orchestration with quality gates $46,000, turnaround time monitoring $18,000. That totals $172,000 and ships in about 20 weeks.

Phase two adds the variant knowledge base at roughly $95,000, reclassification surveillance at roughly $70,000, templated sign out at roughly $80,000, amended report handling at roughly $55,000, payer aware billing handoff at roughly $60,000 and a second instrument integration at roughly $45,000. That is $405,000, taking the platform to $577,000 across about 14 months. At 400 cases a month the per case interpretation fee is the number to compare against, and the knowledge base is the part that stops being a cost and starts being an asset.

Timeline and what actually gates it

Twenty weeks for a first release, and the gate is the assay and specimen data model. Getting the laboratory director, the bioinformatics lead and the pathologists signing reports to agree how an assay version relates to a report and to a classification takes longer than building any single component. It cannot be deferred, because every later feature depends on the answer.

The second gate is validation of the pipeline orchestration against your existing results. Run a set of previously reported cases end to end through the new system and reconcile every difference before go live. Differences will appear, most of them will be explainable, and the ones that are not are exactly what this exercise is for.

Costs that sit outside the software quote

Two lines belong in the business case and never in a build quote. The first is reference and annotation source licensing. Some of what a clinical report depends on is freely available and some is commercially licensed, and the licensed portion is payable whether your platform is custom or bought. Get those quotes during scoping so the comparison against a per case vendor fee is honest.

The second is compute for reanalysis. Reclassification surveillance and cohort requeries mean rerunning old data, and that compute is a real recurring cost that grows with your accumulated case volume rather than with your current monthly throughput. Laboratories that budget compute against this month's cases are always short.

The ongoing costs nobody quotes

• Maintenance at 20 to 28 percent of build cost per year. High, because anything touching pipeline, classification or report content carries validation impact assessment before it ships.
• Per assay launch at $25,000 to $60,000 each. The pipeline version, report template, thresholds and validation package for every new assay. This is the recurring line laboratories consistently omit and it is the largest one.
• Annotation source updates. Sources release on their own cadence and each update has to be applied without changing the meaning of already signed reports, which means pinning versions and reporting against them deliberately.
• Compute for reanalysis. Grows with accumulated cases, not with monthly volume. Model it over five years rather than one.
• Sign out training at $8,000 to $20,000 a year. Pathologists and geneticists join and leave, and the sign out workflow is where an untrained user does the most damage.

When you should not build

A laboratory running two fixed panels at low volume should buy SOPHiA GENETICS, PierianDx or an equivalent and spend the money on sequencing capacity instead. At that scale the per case fee is smaller than the maintenance and per assay launch costs of a custom platform, and the vendor's knowledge base is better than the one you would accumulate.

The build case turns when you launch your own assays, report more than roughly 300 cases a month, or are paying per case to an interpretation vendor while still running the wet laboratory on spreadsheets. The strongest argument is ownership of the variant knowledge base, because a laboratory that has classified thousands of variants with its own evidence holds something it cannot buy back later. Before committing, add up twelve months of per case fees and per assay vendor charges, then compare that against the build plus its recurring lines over five years.

If you would rather scope this before committing budget, Digital Heroes contracts through India LLP, US LLC and UK LTD entities, so the agreement and the intellectual property assignment sit under law your own advisers already read. Nothing about that commits you to the build.